Congo: More than 6,000 Ebola cases Still no end in sight to the outbreak

Ebola vaccinations have begun in the Democratic Republic of Congo using a vaccine developed against a different strain of the virus, according to medical experts. The initiative aims to reduce disease severity and mortality rates among affected populations, though it is unlikely to halt the ongoing outbreak. The efforts are part of a broader strategy involving ring vaccination and clinical trials to assess the effectiveness of existing vaccines against the current strain known as Bundibugyo. The vaccination campaign started with a vaccine originally designed for the Zaire ebolavirus, which differs significantly from the Bundibugyo variant currently circulating in eastern DRC. According to Dr. Leif Erik Sander, director of the clinic for infectious diseases and intensive care at Charité in Berlin, this vaccine does not offer complete protection but could potentially lead to fewer severe cases and lower fatality rates. He emphasized that while the vaccine might help mitigate some aspects of the outbreak, it is not expected to end the epidemic or prevent future outbreaks entirely. Dr. Sander noted that research into a specific vaccine for the Bundibugyo strain is already underway. Two potential candidates, developed by Oxford University and Moderna, are in phase one of testing, with phase two preparations already completed. These vaccines require further months of development before reaching phase three, which is projected to occur in 2027. Despite progress, the process remains slow due to logistical and procedural requirements similar to those encountered during the global response to the coronavirus pandemic. The World Health Organization has allocated 70,000 doses of the existing Ebola vaccine for use in the region. This stockpile includes provisions for ring vaccination strategies, which involve immunizing individuals at the periphery of affected areas before moving inward. Such methods aim to contain outbreaks by creating barriers of immunity around infected zones rather than attempting to suppress them from within. Dr. Sander explained that this approach makes sense because it is more challenging to control an outbreak from its epicenter. Of the 70,000 doses, 50,000 are intended for frontline healthcare workers and personnel directly involved in combating the outbreak. An additional 20,000 doses will be used in clinical studies to evaluate the vaccine’s efficacy. Participants in these studies will be selected randomly through a lottery system, receiving either the actual vaccine or a placebo. Certain groups, such as those with pre-existing health conditions, will be excluded, and children will not be prioritized for participation. The delay in initiating the vaccination program, nearly four months after the WHO officially declared the outbreak in mid-May, has raised questions about the challenges faced in implementing public health measures in the region. Dr. Sander acknowledged the complexity of operating in an area marked by instability and conflict, which complicates both containment efforts and the distribution of medical resources. Attacks on treatment centers have further hindered the response, adding layers of difficulty to an already complex situation. Healthcare workers and local communities continue to grapple with the dual threats of the virus itself and the obstacles posed by security concerns and limited infrastructure. While the current vaccination effort offers hope for reducing the impact of the outbreak, the long-term solution depends on the successful development and deployment of a targeted vaccine for the Bundibugyo strain. Until then, the focus remains on mitigating the spread and protecting vulnerable populations through available interventions.